CaraVan Biologix is a biotechnology company focused on creating benefits to broad patient
populations by addressing the limitations of whole cell chimeric receptor therapeutics.
Our novel and intellectually protected technology platforms enable us to develop allogenic treatments
for a spectrum of human diseases. CaraVan Biologix medicines are expected to show superior safety
profile to include lower risk for cytokine release syndrome and other adverse immune reactions. Our approach will significantly reduce the complexity of manufacturing cell therapies, enhance blood-brain barrier penetration,
and improve targeted delivery of small molecules and other biologics.
LIMITLESS VISION, OPPORTUNITY, AND CURATIVE POTENTIAL
Our allogenic iPSC-derived mini-CAR™ and mini-VAN™ BioNanoVesicles (BioNVs) can be rapidly designed,
engineered, and manufactured to build our internal pipeline as well as the therapeutics for indications
of interest to strategic partners.
Platform for Stand Alone
Therapeutics or Whole Cell
CaraVan Biologix is developing a next-generation paradigm shifting Mini-CAR™ therapeutic platform that is designed to address the many challenges associated with whole cell CAR-based therapeutics for the treatment of solid tumors and beyond. These challenges include the elimination of cytokine release syndrome, the inaccessibility of solid tumors, therapeutic instability and immune suppression in the solid tumor microenvironment (STME), inefficient cancer biomarker expression and targeting, and exhaustion of naturally occurring immune-mounted cellular responses.
Biomolecular and Small
The delivery of large biomolecules (including gene editors) and small molecules to diseased cells in a highly targeted, efficient, and costly manner remains one of the biggest challenges in biotechnology. CaraVan Biologix is developing its premier Mini-VAN™ delivery platform by integrating and enhancing the natural properties of viral receptors with BioNVs using state of the art Artificial Intelligence design programs
Board of Directors
Science & Business
Each PILLAR of our platform addresses the challenges that whole cell CAR therapeutics have yet to overcome
Each PILLAR addresses the challenges associated with the delivery of large biomolecule delivery systems
For enhanced efficacy CaraVan Biologix deploys three A.I. interfaces to 1) improve the quality of our therapeutics, 2) design biomarker ligands for specific cellular targets and, 3) improve the dosing profiles of our mini-BioNVs.
CaraVan Biologix is focused on rare and hard treat human diseases. Our mission is to develop
state of the art therapeutics to make a genuine difference.
We are continually seeking exceptional pharmaceutical industry professionals who are
passionate about innovating on the forefront of biotechnology to better the lives of patients